A rare case of Takotsubo cardiomyopathy
O. Fiste, C. Trika, N.K. Syrigos, E.A. Kotteas Third Department of Medicine, Oncology Unit, National and Kapodistrian University of Athens, Athens, Greece. ofiste@med.uoa.gr
BACKGROUND: The recent advent of the cyclin-dependent kinase (CDK) 4/6 inhibitors has considerably evolved hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer treatment. Palbociclib, an orally administered pyridopyrimidine derivative, was the first CDK4/6 inhibitor to be introduced into daily clinical practice in combination with classic endocrine backbone, based on progression-free survival (PFS) benefit assessed in the pivotal PALOMA series of randomized clinical trials. Regarding its safety profile, neutropenia and leukopenia are the most common and well-defined adverse effects, while cardiac complications are rather scarce.
CASE REPORT: We present the rare case of a middle-aged female patient with HR+/HER2- metastatic breast cancer, without prior exposure to cardiotoxic antineoplastic agents, who developed Takotsubo cardiomyopathy (TTC) in the context of systemic therapy with palbociclib plus letrozole combination.
CONCLUSIONS: Pharmacovigilance and experimental studies are warranted to confirm any causative relationship and to explore the underlying pathophysiology, respectively.
Free PDF Download![Creative Commons License](https://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
O. Fiste, C. Trika, N.K. Syrigos, E.A. Kotteas
A rare case of Takotsubo cardiomyopathy
Eur Rev Med Pharmacol Sci
Year: 2024
Vol. 28 - N. 5
Pages: 2063-2067
DOI: 10.26355/eurrev_202403_35619